Chukwuemeka Christian Aghasili
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Chukwuemeka Christian Aghasili has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Abdul-Azeez Muhammed Usman
Royal Stoke University Hospital, Stoke-on-Trent, UK
1 shared publication - Adam Friedman
SUNY Downstate University, Brooklyn, USA
1 shared publication - Adetayo Y. Odueke
University of Arkansas for Medical Sciences, Northwest Regional Campus, Fayetteville, USA
1 shared publication - Akua Koaso Yalley
Department of Medical Laboratory Sciences School of Biomedical and Allied Health Sciences University of Ghana Accra Ghana
1 shared publication - Albert Orhin
Johns Hopkins Bloomberg School of Public Health Baltimore Maryland USA
1 shared publication - Benjamin Pulle Niriwa
Department of Medical Microbiology, University of Ghana Medical School, Accra P.O. Box KB 4236, Ghana
1 shared publication
Latest Publications
- 5 May 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (5) , e70681
Trends in Cardiovascular Mortality Associated With Systemic Connective Tissue Disorders in the United States: A 22‐Year Population‐Based National Analysis (1999–2020)
Aim: To examine national trends and disparities in cardiovascular mortality associated with systemic connective tissue disorders (CTDs) in the United States from 1999 to 2020. Methods: We analyzed mortality data from the CDC WONDER database. Deaths were included where CTD (ICD‐10: M05, M06, M30–M35) was the underlying cause and cardiovascular disease was a contributing cause. Age‐adjusted mortality rates (AAMRs) per 1 000 000 were calculated using the 2000 US Standard Population. Joinpoint regression identified annual and average annual percentage changes. Analyses were stratified by sex, race/ethnicity, census region, and urbanization. Disease subgroup and state‐level analyses were performed. Results: Between 1999 and 2020, 47 752 cardiovascular deaths occurred among individuals with systemic CTDs. The national AAMR declined from 14.4 to 8.2 per 1 000 000 (AAPC: −2.68%, 95% CI: −2.89 to −2.47, p < 0.001). Females had consistently higher mortality than males (average AAMR: 13.5 vs. 5.9 per 1 000 000; p < 0.001). Non‐Hispanic Black individuals had the highest rates (average AAMR: 14.9 per 1 000 000), with widening disparities after 2008. Rural areas had higher mortality than urban areas (average AAMR: 11.4 vs. 9.9 per 1 000 000; p = 0.01). Subgroup analyses revealed heterogeneous trends across CTD subtypes, with SLE showing the slowest improvement (AAPC: −1.87%) and dermatomyositis the steepest decline (AAPC: −4.98%). State‐level AAMRs ranged 2.2‐fold, from 6.3 (District of Columbia) to 13.6 (Montana) per 1 000 000. Conclusions: Cardiovascular mortality associated with systemic CTDs has declined significantly over two decades; however, persistent racial disparities, urban–rural differences, heterogeneous disease‐specific trends, and substantial geographic variation underscore the need for targeted, equitable interventions in this high‐risk population.
- 5 May 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (5) , e70681
Trends in Cardiovascular Mortality Associated With Systemic Connective Tissue Disorders in the United States: A 22‐Year Population‐Based National Analysis (1999–2020)
Aim: To examine national trends and disparities in cardiovascular mortality associated with systemic connective tissue disorders (CTDs) in the United States from 1999 to 2020. Methods: We analyzed mortality data from the CDC WONDER database. Deaths were included where CTD (ICD‐10: M05, M06, M30–M35) was the underlying cause and cardiovascular disease was a contributing cause. Age‐adjusted mortality rates (AAMRs) per 1 000 000 were calculated using the 2000 US Standard Population. Joinpoint regression identified annual and average annual percentage changes. Analyses were stratified by sex, race/ethnicity, census region, and urbanization. Disease subgroup and state‐level analyses were performed. Results: Between 1999 and 2020, 47 752 cardiovascular deaths occurred among individuals with systemic CTDs. The national AAMR declined from 14.4 to 8.2 per 1 000 000 (AAPC: −2.68%, 95% CI: −2.89 to −2.47, p < 0.001). Females had consistently higher mortality than males (average AAMR: 13.5 vs. 5.9 per 1 000 000; p < 0.001). Non‐Hispanic Black individuals had the highest rates (average AAMR: 14.9 per 1 000 000), with widening disparities after 2008. Rural areas had higher mortality than urban areas (average AAMR: 11.4 vs. 9.9 per 1 000 000; p = 0.01). Subgroup analyses revealed heterogeneous trends across CTD subtypes, with SLE showing the slowest improvement (AAPC: −1.87%) and dermatomyositis the steepest decline (AAPC: −4.98%). State‐level AAMRs ranged 2.2‐fold, from 6.3 (District of Columbia) to 13.6 (Montana) per 1 000 000. Conclusions: Cardiovascular mortality associated with systemic CTDs has declined significantly over two decades; however, persistent racial disparities, urban–rural differences, heterogeneous disease‐specific trends, and substantial geographic variation underscore the need for targeted, equitable interventions in this high‐risk population.
- 30 August 2025
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 26 (1) , 35-57
Advances in Non-statin Lipid Therapies: A Narrative Review of Evolving Strategies for Cardiovascular Risk Reduction
Despite the well-established benefits of statin therapy in reducing atherosclerotic cardiovascular disease (ASCVD) risk, many patients fail to achieve recommended low-density lipoprotein cholesterol (LDL-C) targets or experience statin intolerance, necessitating alternative approaches. This review examines advances in non-statin lipid-lowering therapies, focusing on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (monoclonal antibodies and inclisiran), bempedoic acid, and other non-statin lipid medications. We evaluate their mechanisms of action, clinical efficacy, and safety profiles on the basis of landmark trials. A conceptual framework for personalized lipid management is proposed, addressing residual cardiovascular risk, statin intolerance, and complex patient profiles. Clinical decision pathways are presented for high-risk patients, statin-intolerant individuals, and those with adherence challenges. We explore emerging therapies targeting novel pathways, including lipoprotein(a), apolipoprotein C-III inhibitors, angiopoietin-like protein 3 (ANGPTL3) inhibitors, cholesteryl ester transfer protein (CETP) inhibitors, and gene-editing technologies. Implementation barriers, including cost considerations, insurance challenges, and global access disparities, are discussed alongside solutions.
- 30 August 2025
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 26 (1) , 35-57
Advances in Non-statin Lipid Therapies: A Narrative Review of Evolving Strategies for Cardiovascular Risk Reduction
Despite the well-established benefits of statin therapy in reducing atherosclerotic cardiovascular disease (ASCVD) risk, many patients fail to achieve recommended low-density lipoprotein cholesterol (LDL-C) targets or experience statin intolerance, necessitating alternative approaches. This review examines advances in non-statin lipid-lowering therapies, focusing on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (monoclonal antibodies and inclisiran), bempedoic acid, and other non-statin lipid medications. We evaluate their mechanisms of action, clinical efficacy, and safety profiles on the basis of landmark trials. A conceptual framework for personalized lipid management is proposed, addressing residual cardiovascular risk, statin intolerance, and complex patient profiles. Clinical decision pathways are presented for high-risk patients, statin-intolerant individuals, and those with adherence challenges. We explore emerging therapies targeting novel pathways, including lipoprotein(a), apolipoprotein C-III inhibitors, angiopoietin-like protein 3 (ANGPTL3) inhibitors, cholesteryl ester transfer protein (CETP) inhibitors, and gene-editing technologies. Implementation barriers, including cost considerations, insurance challenges, and global access disparities, are discussed alongside solutions.
- Open Access
- 26 March 2021
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (7) , 3468
Unravelling the Perspectives of Day and Night Traders in Selected Markets within a Sub-Saharan African City with a Malaria Knowledge, Attitude and Practice Survey
Background: Malaria is still endemic in sub-Saharan Africa, with a high disease burden. Misconceptions about malaria contribute to poor attitudes and practices, further increasing the burden in endemic countries. Studies have examined the knowledge, attitudes, and practices (KAP) of malaria among different populations. However, there seems to be no available literature reporting on the perspectives of day and night market traders. To the best of our knowledge, this is the first report on malaria KAP with a focus on day and night market traders. Methods: A descriptive cross-sectional study involving day and night market traders in 10 selected markets within the Greater Accra Region of Ghana was carried out. Data were collected from consenting respondents using a structured questionnaire. Results: Of the 760 respondents (33.3% (n = 253) night and 66.7% (n = 507) day traders) interviewed, there was no significant difference between the day and night market traders in terms of malaria KAP. Although the market traders had an overall moderate knowledge (54.0% of the day traders and 56.5% of the night traders), misconceptions about malaria (especially that it could be caused by exposure to the sun) still existed among the traders. Moreover, the majority of the traders who demonstrated high knowledge (43.98%, n = 250) did not always take laboratory tests to confirm their suspicion, indicating poor attitude. Furthermore, the market traders’ choice of drug for malaria treatment (p = 0.001) and preferred malaria treatment type (orthodox or herbal) (p = 0.005) were significantly associated with their knowledge level. Conclusions: Despite the observation that no significant difference in KAP exists between day and night market traders, appropriate health education programs and interventions still need to be directed at misconceptions, poor attitudes, and poor practices revealed by this study. This will ultimately help in the prevention and control of malaria in Ghana, and globally.
- 26 March 2021
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (7) , 3468
Open AccessUnravelling the Perspectives of Day and Night Traders in Selected Markets within a Sub-Saharan African City with a Malaria Knowledge, Attitude and Practice Survey
Background: Malaria is still endemic in sub-Saharan Africa, with a high disease burden. Misconceptions about malaria contribute to poor attitudes and practices, further increasing the burden in endemic countries. Studies have examined the knowledge, attitudes, and practices (KAP) of malaria among different populations. However, there seems to be no available literature reporting on the perspectives of day and night market traders. To the best of our knowledge, this is the first report on malaria KAP with a focus on day and night market traders. Methods: A descriptive cross-sectional study involving day and night market traders in 10 selected markets within the Greater Accra Region of Ghana was carried out. Data were collected from consenting respondents using a structured questionnaire. Results: Of the 760 respondents (33.3% (n = 253) night and 66.7% (n = 507) day traders) interviewed, there was no significant difference between the day and night market traders in terms of malaria KAP. Although the market traders had an overall moderate knowledge (54.0% of the day traders and 56.5% of the night traders), misconceptions about malaria (especially that it could be caused by exposure to the sun) still existed among the traders. Moreover, the majority of the traders who demonstrated high knowledge (43.98%, n = 250) did not always take laboratory tests to confirm their suspicion, indicating poor attitude. Furthermore, the market traders’ choice of drug for malaria treatment (p = 0.001) and preferred malaria treatment type (orthodox or herbal) (p = 0.005) were significantly associated with their knowledge level. Conclusions: Despite the observation that no significant difference in KAP exists between day and night market traders, appropriate health education programs and interventions still need to be directed at misconceptions, poor attitudes, and poor practices revealed by this study. This will ultimately help in the prevention and control of malaria in Ghana, and globally.